Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model
Open Access
- 21 July 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (20), 3906-3913
- https://doi.org/10.1093/hmg/ddp333
Abstract
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality and is caused by the loss of a functional SMN1 gene. In humans, there exists a nearly-identical copy gene known as SMN2 that encodes an identical protein as SMN1, but differs by a silent C to T transition within exon 7. This single nucleotide difference produces an alternatively spliced isoform, SMNΔ7, which encodes a rapidly degraded protein. The absence of the short peptide encoded by SMN exon 7 is critical in the disease development process; however, heterologous sequences can partially compensate for the SMN exon 7 peptide in several cellular assays. Consistent with this, aminoglycosides, compounds that can suppress efficient recognition of stop codons, resulted in significantly increased levels of SMN protein in SMA patient fibroblasts. We now examine the potential therapeutic capabilities of a novel aminoglycoside, TC007. In an intermediate SMA model (Smn−/−; SMN2+/+; SMNΔ7), when delivered directly to the central nervous system (CNS), TC007 induces SMN in both the brain and spinal cord, significantly increases lifespan (∼30%) and increases ventral horn cell number, consistent with its ability to increase SMN levels in induced pluripotent stem cell-derived human SMA motor neuron cultures. Collectively, these experiments are the first in vivo examination of therapeutics for SMA designed to induce read-through of the SMNΔ7 stop codon to show increased benefit by direct administration to the CNS.Keywords
This publication has 60 references indexed in Scilit:
- Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophyHuman Molecular Genetics, 2009
- Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivoHuman Molecular Genetics, 2009
- Induced pluripotent stem cells from a spinal muscular atrophy patientNature, 2008
- Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophyHuman Molecular Genetics, 2008
- A SMNΔ7 read-through product confers functionality to the SMNΔ7 proteinNeuroscience Letters, 2008
- Embryonic motor axon development in the severe SMA mouseHuman Molecular Genetics, 2008
- Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophyHuman Molecular Genetics, 2008
- SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in SplicingCell, 2008
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences of the United States of America, 2008
- Abnormal motor phenotype in the SMNΔ7 mouse model of spinal muscular atrophyNeurobiology of Disease, 2007